Detailed information for compound 66967
Basic information
Technical information
- Name: Unnamed compound
- MW: 574.427 | Formula: C23H32FIN4O4
-
H donors: 2
H acceptors: 2
LogP: 3.67
Rotable bonds: 11
Rule of 5 violations (Lipinski): 2 - SMILES: CC(NC(=O)OCc1c(COC(=O)NC(C)C)c2n(c1c1cc[n+](c(c1)F)C)CCC2)C.[I-]
- InChi: 1S/C23H31FN4O4.HI/c1-14(2)25-22(29)31-12-17-18(13-32-23(30)26-15(3)4)21(28-9-6-7-19(17)28)16-8-10-27(5)20(24)11-16;/h8,10-11,14-15H,6-7,9,12-13H2,1-5H3,(H-,25,26,29,30);1H
- InChiKey: DYRDFTDMVTZSIO-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
No curated genes were found associated with this compound
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Loa Loa (eye worm) | hypothetical protein | 0.0101 | 0.3773 | 0.3808 |
| Echinococcus granulosus | sodium channel protein | 0.0047 | 0.1418 | 0.1418 |
| Echinococcus granulosus | potassium voltage gated channel subfamily D | 0.0044 | 0.1302 | 0.1302 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.002 | 0.0242 | 0.0242 |
| Loa Loa (eye worm) | TKL/RAF/RAF protein kinase | 0.0139 | 0.5427 | 0.5478 |
| Brugia malayi | Voltage-gated potassium channel, Shal-family (KCND, Kv4-like) alpha-subunit. C. elegans shl-1 ortholog | 0.0089 | 0.3238 | 0.3191 |
| Brugia malayi | Voltage-gated potassium channel, Shaker-family (KCNA, Kv1-like) alpha-subunit | 0.0101 | 0.3773 | 0.376 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.0055 | 0.1798 | 0.1798 |
| Leishmania major | calcium channel protein, putative,ion transporter, putative | 0.0047 | 0.1418 | 0.5 |
| Echinococcus multilocularis | raf serine:threonine protein kinase | 0.0245 | 1 | 1 |
| Echinococcus granulosus | potassium voltage gated channel subfamily D | 0.0035 | 0.0907 | 0.0907 |
| Echinococcus granulosus | potassium voltage gated channel subfamily D | 0.002 | 0.0242 | 0.0242 |
| Brugia malayi | Voltage-gated potassium channel, Shab-family (KCNB, Kv2-like) alpha-subunit | 0.0046 | 0.1403 | 0.1237 |
| Loa Loa (eye worm) | Kv4.2 voltage-gated potassium channel | 0.0034 | 0.0853 | 0.0861 |
| Echinococcus multilocularis | voltage gated potassium channel | 0.0036 | 0.0954 | 0.0848 |
| Loa Loa (eye worm) | raf kinase | 0.0243 | 0.9907 | 1 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.002 | 0.0242 | 0.0242 |
| Brugia malayi | hypothetical protein | 0.0105 | 0.3944 | 0.3943 |
| Echinococcus granulosus | potassium voltage gated channel protein | 0.0099 | 0.3687 | 0.3687 |
| Loa Loa (eye worm) | hypothetical protein | 0.0105 | 0.3944 | 0.3981 |
| Echinococcus multilocularis | sodium channel protein | 0.0047 | 0.1418 | 0.1318 |
| Schistosoma mansoni | vesicular amine transporter | 0.003 | 0.0696 | 0.0696 |
| Echinococcus granulosus | shaker cognate | 0.0055 | 0.1798 | 0.1798 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.0101 | 0.3773 | 0.3773 |
| Echinococcus multilocularis | shaker cognate | 0.0055 | 0.1798 | 0.1702 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.0099 | 0.3687 | 0.3687 |
| Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.0242 | 0.0244 |
| Loa Loa (eye worm) | hypothetical protein | 0.0017 | 0.0116 | 0.0117 |
| Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.0907 | 0.0916 |
| Echinococcus multilocularis | potassium voltage gated channel subfamily D | 0.002 | 0.0242 | 0.0128 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.0101 | 0.3773 | 0.3773 |
| Loa Loa (eye worm) | hypothetical protein | 0.0017 | 0.0116 | 0.0117 |
| Echinococcus multilocularis | potassium voltage gated channel subfamily C | 0.002 | 0.0242 | 0.0128 |
| Echinococcus multilocularis | potassium voltage gated channel protein | 0.0099 | 0.3687 | 0.3613 |
| Echinococcus multilocularis | potassium voltage gated channel subfamily D | 0.0035 | 0.0907 | 0.0801 |
| Brugia malayi | Raf kinase | 0.0237 | 0.9632 | 1 |
| Loa Loa (eye worm) | voltage-gated potassium channel | 0.0055 | 0.1798 | 0.1815 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.002 | 0.0242 | 0.0242 |
| Loa Loa (eye worm) | TK/KIN16 protein kinase | 0.0172 | 0.682 | 0.6884 |
| Echinococcus granulosus | voltage gated sodium channel Nav1 alpha subunit | 0.0047 | 0.1418 | 0.1418 |
| Onchocerca volvulus | Tyrosine kinase homolog | 0.016 | 0.6334 | 1 |
| Echinococcus multilocularis | transfer RNA-Gly | 0.002 | 0.0242 | 0.0128 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.0089 | 0.3238 | 0.3238 |
| Schistosoma mansoni | serine/threonine protein kinase | 0.0245 | 1 | 1 |
| Echinococcus granulosus | potassium voltage gated channel subfamily C | 0.002 | 0.0242 | 0.0242 |
| Echinococcus granulosus | potassium voltage gated channel protein | 0.0055 | 0.1798 | 0.1798 |
| Echinococcus multilocularis | potassium voltage gated channel protein | 0.0055 | 0.1798 | 0.1702 |
| Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.0907 | 0.0916 |
| Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0172 | 0.682 | 0.7005 |
| Echinococcus granulosus | potassium voltage gated channel protein | 0.0101 | 0.3773 | 0.3773 |
| Echinococcus granulosus | potassium voltage gated channel protein | 0.0035 | 0.0907 | 0.0907 |
| Echinococcus multilocularis | potassium voltage gated channel protein | 0.0101 | 0.3773 | 0.37 |
| Echinococcus multilocularis | potassium voltage gated channel subfamily A | 0.0092 | 0.3378 | 0.3301 |
| Echinococcus multilocularis | conserved hypothetical protein | 0.0035 | 0.0907 | 0.0801 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.002 | 0.0242 | 0.0242 |
| Echinococcus multilocularis | potassium voltage gated channel subfamily D | 0.0044 | 0.1302 | 0.12 |
| Schistosoma mansoni | voltage-gated potassium channel | 0.0046 | 0.1403 | 0.1403 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.1403 | 0.1416 |
| Brugia malayi | Voltage-gated potassium channel, Shab-family (KCNB, Kv2-like) alpha-subunit. C. elegans exp-2 ortholog | 0.0055 | 0.1798 | 0.1657 |
| Loa Loa (eye worm) | voltage-gated potassium channel | 0.0025 | 0.0458 | 0.0463 |
| Echinococcus granulosus | voltage gated potassium channel | 0.002 | 0.0242 | 0.0242 |
| Echinococcus granulosus | potassium voltage gated channel subfamily A | 0.0101 | 0.3773 | 0.3773 |
| Echinococcus granulosus | roundabout 2 | 0.0017 | 0.0116 | 0.0116 |
| Echinococcus granulosus | Potassium voltage gated channel protein Shaw | 0.002 | 0.0242 | 0.0242 |
| Echinococcus multilocularis | voltage gated potassium channel | 0.002 | 0.0242 | 0.0128 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| BWD (functional) | = -7.6 g | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 100mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = -7.6 g | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 100mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = -1.3 g | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 12.5mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = -1.3 g | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 12.5mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = -1 g | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 25mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = -1 g | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 25mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = -0.8 g | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 50mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = -0.8 g | In vivo activity against murine L1210 tumour system at the dose of 50mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = -0.8 g | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 50mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = -0.8 g | In vivo activity against murine L1210 tumour system at the dose of 50mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = 0.2 g | In vivo activity against murine MX-1 tumour system at the dose of 75mg/kg, activity expressed as body weight difference. | ChEMBL. | 2342060 |
| BWD (functional) | = 0.2 g | In vivo activity against murine MX-1 tumour system at the dose of 75mg/kg, activity expressed as body weight difference. | ChEMBL. | 2342060 |
| BWD (functional) | = 0.3 g | In vivo activity against murine MX-1 tumour system at the dose of 37.5mg/kg, activity expressed as body weight difference. | ChEMBL. | 2342060 |
| BWD (functional) | = 0.3 g | In vivo activity against murine MX-1 tumour system at the dose of 37.5mg/kg, activity expressed as body weight difference. | ChEMBL. | 2342060 |
| BWD (functional) | = 0.4 g | In vivo activity against murine M5076 tumour system at the dose of 25mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = 0.6 g | In vivo activity against murine L1210 tumour system at the dose of 25mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = 0.6 g | In vivo activity against murine L1210 tumour system at the dose of 25mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| BWD (functional) | = 1.4 g | In vivo activity against murine M5076 tumour system at the dose of 50mg/kg, activity expressed as body weight difference | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.0044 min-1 | Effect of pH on the hydrolysis of pyridinium Moity in 0.05 M buffer concentration at the pH 6.0 | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.0052 min-1 | Effect of phosphate buffer concentration on the hydrolysis of alpha Fluoropyridinium Moity at the concentration of 0.02M, pH 6.5, 25 degree C. | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.007 min-1 | Effect of Ionic strength (1.0M NaCl)on the hydrolysis of pyridinium Moity in 0.02 M buffer concentration, pH 7.4,25 degree C | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.0072 min-1 | Effect of phosphate buffer on the hydrolysis of alpha Fluoropyridinium Moity at the concentration of 0.05M, pH 6.5, 25 degree C | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.011 min-1 | Effect of Ionic strength (0.50 M NaCl)on the hydrolysis of pyridinium Moity in 0.02 M buffer concentration, pH 7.4,25 degree C | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.0132 min-1 | Effect of phosphate buffer on the hydrolysis of alpha Fluoropyridinium Moity at the concentration of 0.02M, pH 8.0, 25 degree C | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.0138 min-1 | Effect of phosphate buffer on the hydrolysis of alpha Fluoropyridinium Moity at the concentration of 0.10M, pH 6.5, 25 degree C | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.0153 min-1 | Effect of pH on the hydrolysis of pyridinium Moity in 0.05 M buffer concentration at the pH 6.5 | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.02 min-1 | Effect of phosphate buffer on the hydrolysis of alpha Fluoropyridinium Moity at the concentration of 0.05M, pH 8.0,25degree C | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.02 min-1 | Effect of Ionic strength (0.25 M NaCl)on the hydrolysis of pyridinium Moity in 0.02 M buffer concentration, pH 7.4,25 degree C | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.0208 min-1 | Effect of pH on the hydrolysis of pyridinium Moity in 0.05 M buffer concentration at the pH 7.0 | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.024 min-1 | Effect of Ionic strength (0.10 M NaCl)on the hydrolysis of pyridinium Moity in 0.02 M buffer concentration, pH 7.4,25 degree C | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.0337 min-1 | Effect of pH on the hydrolysis of pyridinium Moity in 0.05 M buffer concentration at the pH 7.4 | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.036 min-1 | Effect of phosphate buffer on the hydrolysis of alpha Fluoropyridinium Moity at the concentration of 0.10M, pH 8.0, 25 degree C. | ChEMBL. | 2342060 |
| K obs (ADMET) | = 0.052 min-1 | Effect of pH on the hydrolysis of pyridinium Moity in 0.05 M buffer concentration at the pH 8.0 | ChEMBL. | 2342060 |
| KE (functional) | = -2.08 | In vivo activity against murine L1210 tumour system at the dose of mg/kg, activity expressed as KE | ChEMBL. | 2342060 |
| KE (functional) | = -1.98 | In vivo activity against murine M5076 tumour system at the dose of 25mg/kg, activity expressed as KE | ChEMBL. | 2342060 |
| KE (functional) | = -1.94 | In vivo activity against murine L1210 tumour system at the dose of 50mg/kg, activity expressed as KE | ChEMBL. | 2342060 |
| KE (functional) | = -1.59 | In vivo activity against murine M5076 tumour system at the dose of 50mg/kg, activity expressed as KE | ChEMBL. | 2342060 |
| KE (functional) | = 0.75 | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 12.5mg/kg,activity expressed as KE | ChEMBL. | 2342060 |
| KE (functional) | = 1.25 | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of mg/kg,activity expressed as KE | ChEMBL. | 2342060 |
| KE (functional) | = 1.32 | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 50mg/kg,activity expressed as KE | ChEMBL. | 2342060 |
| T/C (functional) | = 34 % | In vivo activity against murine MX-1 tumour system at the dose of 75mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 34 % | In vivo activity against murine MX-1 tumour system at the dose of 75mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 69 % | In vivo activity against murine MX-1 tumour system at the dose of 37.5mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 69 % | In vivo activity against murine MX-1 tumour system at the dose of 37.5mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 104 % | In vivo activity against murine M5076 tumour system at the dose of 25mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 118 % | In vivo activity against murine L1210 tumour system at the dose of 50mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 118 % | In vivo activity against murine L1210 tumour system at the dose of 25mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 118 % | In vivo activity against murine M5076 tumour system at the dose of 50mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 118 % | In vivo activity against murine L1210 tumour system at the dose of 50mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 118 % | In vivo activity against murine L1210 tumour system at the dose of 25mg/kg, activity expressed as %T/C. | ChEMBL. | 2342060 |
| T/C (functional) | = 141 % | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 25mg/kg,activity expressed as % T/C | ChEMBL. | 2342060 |
| T/C (functional) | = 141 % | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 25mg/kg,activity expressed as % T/C | ChEMBL. | 2342060 |
| T/C (functional) | = 149 % | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 12.5mg/kg,activity expressed as % T/C | ChEMBL. | 2342060 |
| T/C (functional) | = 149 % | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 12.5mg/kg,activity expressed as % T/C | ChEMBL. | 2342060 |
| T/C (functional) | = 157 % | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 50mg/kg,activity expressed as % T/C | ChEMBL. | 2342060 |
| T/C (functional) | = 157 % | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 50mg/kg,activity expressed as % T/C | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 13.3 min | Half life of the compound at the pH 8.0 | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 19.25 min | Half life of the compound at the buffer concentration of 0.10 M. | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 20.5 min | Half life of the compound at the pH 7.4 | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 29.1 min | Half life of the compound at the ionic strength 0.10 M NaCl | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 33.8 min | Half life of the compound at the pH 7.0 | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 33.9 min | Half life of the compound at the ionic strength 0.10 M NaCl | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 34.65 min | Half life of the compound at the buffer concentration of 0.05 M. | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 45.3 min | Half life of the compound at the pH 6.5 | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 50.3 min | Half life of the compound at the buffer concentration of 0.10 M. | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 52.5 min | Half life of the compound at the buffer concentration of 0.02 M. | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 63.2 min | Half life of the compound at the ionic strength 0.50 M NaCl | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 96.2 min | Half life of the compound at the concentration of 0.02 M. | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 99.1 min | Half life of the compound at the ionic strength 1.0 M NaCl | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 133.3 min | Half life of the compound at the concentration of 0.02 M. | ChEMBL. | 2342060 |
| T1/2 (ADMET) | = 157.5 min | Half life of the compound at the pH 6.0 | ChEMBL. | 2342060 |
| TDS (functional) | = 0 | In vivo activity against murine L1210 tumour system at the dose of 100mg/kg, activity expressed as TDS; 0/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 0 | In vivo activity against murine MX-1 tumour system at the dose of 150mg/kg, activity expressed as TDS; 0/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 1 | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 100mg/kg,activity expressed as TDS; 1/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 4 | In vivo activity against murine MX-1 tumour system at the dose of 75mg/kg, activity expressed as TDS; 4/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 4 | In vivo activity against murine MX-1 tumour system at the dose of 37.5mg/kg, activity expressed as TDS; 4/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 5 | In vivo activity against murine L1210 tumour system at the dose of 50mg/kg, activity expressed as TDS; 5/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 6 | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 50mg/kg,activity expressed as TDS; 6/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 6 | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 25mg/kg,activity expressed as TDS; 6/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 6 | In vivo activity against P388 Lymphocytic Leukemia in CD2F1 mice at the dose of 12.5mg/kg,activity expressed as TDS; 6/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 6 | In vivo activity against murine L1210 tumour system at the dose of 25mg/kg, activity expressed as TDS; 6/6 | ChEMBL. | 2342060 |
| TDS (functional) | = 6 | In vivo activity against murine M5076 tumour system at the dose of 100mg/kg, activity expressed as TDS; 6/10 | ChEMBL. | 2342060 |
| TDS (functional) | = 10 | In vivo activity against murine M5076 tumour system at the dose of 50mg/kg, activity expressed as TDS; 10/10 | ChEMBL. | 2342060 |
| TDS (functional) | = 10 | In vivo activity against murine M5076 tumour system at the dose of 25mg/kg, activity expressed as TDS; 10/10 | ChEMBL. | 2342060 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
No external resources registered for this compound
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.